Document is current
Any future updates will be listed below
-
Authors
Karmali, Reem https://orcid.org/0000-0003-0984-4376
Shouse, Geoffrey https://orcid.org/0000-0002-7917-5713
Torka, Pallawi https://orcid.org/0000-0002-1681-5883
Moyo, Tamara K.
Romancik, Jason https://orcid.org/0000-0003-0054-9362
Barta, Stefan K. https://orcid.org/0000-0002-3280-5271
Bhansali, Rahul https://orcid.org/0000-0002-3616-7393
Cohen, Jonathon B.
Shah, Nirav N. https://orcid.org/0000-0002-4336-1071
Zurko, Joanna
Kenkre, Vaishalee P.
Hess, Brian
Stephens, Deborah M.
Fitzgerald, Lindsey
Ollila, Thomas https://orcid.org/0000-0003-0102-6491
Tabiti, Bukky
Roy, Ishan https://orcid.org/0000-0002-9109-0421
Ma, Shuo https://orcid.org/0000-0002-6139-5486
Winter, Jane
Pro, Barbara
Moreira, Jonathan
Danilov, Alexey V. https://orcid.org/0000-0003-4461-0970
David, Kevin
Gordon, Leo I. https://orcid.org/0000-0003-1666-7064
Epperla, Narendranath https://orcid.org/0000-0002-8216-3457
- License Information
-
More Information
Article History
Received: 3 September 2024
Revised: 4 February 2025
Accepted: 7 March 2025
First Online: 26 March 2025
Competing interests
: NE: Research funding: Beigene, Eli Lilly; Speakers Bureau for Beigene, Incyte, and Novartis; Honoraria/consulting/ad boards for Merck, ADC Therapeutics, Ipsen, Lilly, and Novartis. GS: Advisory boards: Kite, Beigene, AstraZeneca; Speakers Bureau: Kite, Beigene. JR: Research funding: Merck, Corvus Pharmaceuticals, Kymera Therapeutics; Consulting: Acrotech Biopharma, Kyowa Kirin. TKM: Advisory board for Seattle Genetics. TAO: Research support from ONO and LOXO. Consulting for ONO, ADC therapeutics. SM: Research funding: Abbvie, AstraZeneca, BeiGene, Janssen, Juno, Loxo, TG Therapeutics. Speakers Bureau: AstraZeneca, BeiGene, Lilly. Advisory boards: Abbvie, AstraZeneca, BMS, Genentech, Janssen. JNW: Research funding and honoraria from Merck. DMS: consulting fees from Abbvie, AstraZeneca, Beigene, BMS, Celgene, Eli Lilly, Genentech, and Janssen. Institutional research funding from AstraZeneca, Novartis. AVD: consulting fees from Abbvie, AstraZeneca, BeiGene, Bristol Meyers Squibb, Genentech, GenMab, Incyte, Janssen, Lilly Oncology, MEI Pharma, Merck, Nurix and Prelude and has ongoing research funding from Abbvie, AstraZeneca, Bayer Oncology, Beigene, Bristol Meyers Squibb, Cyclacel, GenMab, Lilly Oncology, MEI Pharma, Morphosys and Nurix. NNS: consultancy or advisory committee participation with Miltenyi Biotec, Lilly Oncology, BMS/Juno, Galapagos, Gilead/Kite, Abbvie, Incyte, Seattle Genetics. He has research funding from both Miltenyi Biotec and Lilly Oncology and is on the scientific advisory board for Tundra Therapeutics. SKB: Honoraria: Acrotech, Affimed, Daiichi Sankyo, Kyowa Kirin, Janssen, Seagen. MC: Advisory Board: ADC therapeutics, AstraZeneca, Cellectar, Synthekine; Consultancy: Abbvie: Speaker’s Bureau: Curio Life Sciences, Precision Oncology, Secura Bio. JBC: Consultant/Advisor: AstraZeneca, Abbvie, BeiGene, Janssen, Loxo/Lilly, Kite/Gilead, ADCT; Research Funding: LLS, Genentech, AstraZeneca, Novartis, Loxo/Lilly, BMS/Celgene. ASK: Research funding from AstraZeneca and BeiGene. Advisory boards for AstraZeneca, Abbvie, BeiGene, Bristol-Myers Squibb, Janssen, Kite a Gilead Company, Lox@Lilly. Speakers bureau for BeiGene. RK: Advisory Board: AstraZeneca, BMS, Morphosys/Incyte, Genentech/Roche, Abbvie, Lilly Oncology, Miltenyi; Speakers Bureau: BeiGene, AstraZeneca, Morphosys/Incyte. The remaining authors declare no competing interests.
: Our study was based on data collected from a retrospective chart review. As such, participants were not exposed to greater than minimal risk and, therefore not consented to the study. The protocol was IRB-approved at all participating institutions, including the Northwestern University Central Institutional Review Board (date of approval January 26, 2021) where the data was collated and analyzed. We confirm that all methods were performed in accordance with the relevant guidelines and regulations.
